PharmaTimes December 7, 2022
Data reinforces potential to deliver new standards across HER2-targetable breast cancer
AstraZeneca (AZ) is presenting new data underlining its ambition to redefine care delivery at the 2022 San Antonio Breast Cancer Symposium (SABCS).
Twelve AZ breast cancer medicines and potential new treatments will be highlighted across 55 presentations – including five oral presentations. The company will also showcase the company’s growing leadership throughout different subtypes and stages of the disease.
Two presentations will focus on the DESTINY-Breast clinical programme, demonstrating the efficacy of Enhertu – also known as trastuzumab deruxtecan. The therapy involves patients with HER2-positive metastatic breast cancer.
Meanwhile, updated results from the DESTINY-Breast03 phase 3 trial of Enhertu versus trastuzumab emtansine in patients previously treated with trastuzumab, will...
Today's Sponsors
Today's Sponsor